Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose adjustment of azacitidine versus venetoclax for cytopenias in AML remission
MOH_2022-02-21_010627Phase 2Recruiting
- Sponsor
- ד"ר באהר כריים
- Start
- Sep 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of azacitidine and venetoclax in acute myeloid leukemia (AML) (3 arms), sponsored by ד"ר באהר כריים. Started Sep 2020; status: recruiting.
02
Drugs
azacitidinevenetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on MOH_2022-02-21_010627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-02-21_010627.